Using a comprehensive neuropsychological battery and other measures of motor functioning, researchers examined the relationship between cognitive and clinical factors in adult patients with type 3 SMA.
Researchers assessed patients who developed a new-onset neuromuscular disorder the first 6 weeks after receiving either the first or second dose of the COVID-19 vaccine.
Researchers sought to assess the incidence of Guillain-Barré syndrome following vaccination for Ad.26.COV2.S (Janssen) and mRNA vaccines.
The approval was based on data from a phase 3 study that included 175 adults with generalized myasthenia gravis who were not previously treated with a complement inhibitor.
Researchers sought to evaluate the association between functional test scores recorded at peak age for male children with DMD, and the age of those children at LOA.
Researchers sought to evaluate the safety and efficacy of repeated intravenous cardiosphere-derived cell therapy in patients with late-stage Duchenne muscular dystrophy.
Researchers sought to assess if there were any improvements in the time interval from initial symptoms to diagnosis in a follow-up investigation of patients with DMD born after 2000.
Researchers sought to analyze weight changes during Duchenne muscular dystrophy and the presence of any associations with ambulatory status, caloric intake, or corticosteroid use.
Researchers sought to characterize the association between the expression of the Duchenne muscular dystrophy gene and low-grade glioma survival outcomes.
In a systematic review and meta-analysis, researchers evaluated the evidence of a relationship between muscular dystrophy mutational sites and epilepsy risk.
